FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:1161-1162 October 10, 1996 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Handin, R. I. PubMed Citation

To the Editor: In his editorial on platelets and coronary artery disease (April 25 issue),¹ Handin states, "Aspirin has now become an essential cardiovascular drug, and it is unusual to find patients with established coronary artery disease who do not take it." Sadly, despite overwhelming evidence of the clinical benefit of aspirin in patients with coronary heart disease, many if not most patients with established disease do not take aspirin. Only 37 percent of patients received aspirin in the Scandinavian Simvastatin Survival Study.² Reviewing the treatment of Medicare patients with acute myocardial infarction, the Cooperative Cardiovascular Project found that only . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.